Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- lanreotide
- Lunesta (eszopiclone)
Interactions between your drugs
No drug ⬌ drug interactions were found between the drugs in your list. However, this does not necessarily mean no drug interactions exist. Always consult your healthcare provider.
Drug and food interactions
lanreotide food
Applies to: lanreotide
MONITOR: Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications. Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat. Clinical data are limited, however. In case reports, octreotide has been reported to reduce the relative bioavailability of cyclosporine. Transplant rejection and significant reductions in cyclosporine levels, sometimes to undetectable levels, have been reported in association with the interaction. Vitamin K absorption was not affected when concomitantly administered with lanreotide according to the manufacturer.
MANAGEMENT: Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs. Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.
References (5)
- Landgraf R, Landgraf-Leurs MM, Nusser J, et al. (1987) "Effect of somatostatin analogue (SMS201-995) on cyclosporine levels." Transplantation, 44, p. 724-5
- Ho PJ, Boyajy LD, Greenstein E, Barkan AL (1993) "Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly." Dig Dis Sci, 38, p. 309-15
- Katz MD, Erstad BL (1989) "Octreotide, a new somatostatin analogue." Clin Pharm, 8, p. 255-73
- (2001) "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation
- (2007) "Product Information. Somatuline Depot (lanreotide)." Ipsen Inc
eszopiclone food
Applies to: Lunesta (eszopiclone)
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
ADJUST DOSING INTERVAL: Administration of eszopiclone (the S-enantiomer of zopiclone) with or immediately after a high-fat/heavy meal may delay the onset of hypnotic effects. In healthy adults, administration of a 3 mg dose of eszopiclone after a high-fat meal decreased the mean peak plasma drug concentration (Cmax) by 21% and delayed the time to reach peak plasma drug concentration (Tmax) by approximately 1 hour. Theoretically, this interaction should also affect racemic zopiclone.
MANAGEMENT: Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol. For faster sleep onset, it may be advisable to not administer eszopiclone and zopiclone with or immediately after a high-fat/heavy meal.
References (2)
- (2004) "Product Information. Lunesta (eszopiclone)." Sepracor Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Lutathera
Lutathera is a targeted radiotherapy used for gastroenteropancreatic neuroendocrine tumors ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Somatuline Depot
Somatuline Depot is used as a long-term treatment for acromegaly. Learn about side effects ...
Cometriq
Cometriq (cabozantinib) is used to treat thyroid cancer that has spread to other parts of the body ...
Zortress
Zortress (everolimus) is used to prevent organ rejection in adult kidney transplant recipients ...
Lutetium lu 177 dotatate
Lutetium Lu 177 Dotatate (Lutathera) is a targeted radiotherapy used for gastroenteropancreatic ...
Cabozantinib
Cabozantinib is used for hepatocellular carcinoma, neuroendocrine tumors, renal cell carcinoma ...
Everolimus
Everolimus (Afinitor, Afinitor Disperz, Zortress) belongs to a class of drugs called kinase ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.